medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2022, Number 2

<< Back Next >>

Rev Mex Urol 2022; 82 (2)

Time to PSA nadir as a response factor in CPRC patients treated with abiraterone

Sánchez-Martínez N, Bautista-Vidal C, Morales-Jiménez P, García GE

Language: Spanish
References: 10
Page:
PDF size: 162.28 Kb.


ABSTRACT

Objective: To determine if the time to achieve a PSA nadir is related to a delay in the progression of the disease.
Material and methods: A retrospective study of 36 patients treated with abiraterone acetate in our facilities between January 2014 and May 2018 in CPRC M1 phase. PSA levels are evaluated at the beginning of the treatment, after 4, 8 and 12 weeks, as well as in the successive periods according to our protocol. PSA response is defined as a decrease of ≥30% from the start of treatment and PSA progression as an increase of ≥25% from the beginning. It is considered as ‘progression that supposes withdrawal of treatment’ the one that associates at least two of the following criteria: PSA progression, clinical progression and radiological progression. We performed a linear regression analysis for PSA variables at diagnosis, PSA nadir, time at nadir, PSA doubling time and decrease of at least 30% of the nadir.
Results: In our series, time to nadir in linear regression is positively associated with progression, obtaining better progression-free survival when a longer-term nadir PSA is achieved (p ‹0.018); so that for every month of delay in reaching the nadir, a 0.8 months belated progression is expected.
Conclusion: In our series, achieving a belated PSA nadir is related to an improvement in progression-free survival.


REFERENCES

  1. INE. Distribución de la mortalidad por causas(lista reducida), sexo y edad . Defunciones segúnla causa de muerte (2016). 2016. [accessed 30Apr 2022] Available from: https://www.ine.es/jaxi/Datos.htm?path=/t15/p417/a2016/l0/&file=01003.px

  2. Hussain M, Tangen CM, Higano C,Schelhammer PF, Faulkner J, Crawford ED, etal. Absolute prostate-specific antigen value afterandrogen deprivation is a strong independentpredictor of survival in new metastatic prostatecancer: data from Southwest Oncology GroupTrial 9346 (INT-0162). J Clin Oncol. 2006Aug 20;24(24):3984–90. doi: https://doi.org/10.1200/jco.2006.06.4246

  3. Wu K-J, Pei X-Q, Tian G, Wu D-P, Fan J-H, JiangY-M, et al. PSA time to nadir as a prognosticfactor of first-line docetaxel treatment incastration-resistant prostate cancer: evidencefrom patients in Northwestern China. Asian JAndrol. 2018 Apr;20(2):173–7. doi: https://doi.org/10.4103/aja.aja_34_17

  4. Taussky D, Bedwani S, Meissner N, BaharyJ-P, Lambert C, Barkati M, et al. A comparisonof early prostate-specific antigen declinebetween prostate brachytherapy and differentfractionation of external beam radiation-Impact on biochemical failure. Brachytherapy.2018 Apr;17(2):277–82. doi: https://doi.org/10.1016/j.brachy.2017.11.014

  5. Choueiri TK, Xie W, D’Amico AV, Ross RW,Hu JC, Pomerantz M, et al. Time to prostatespecificantigen nadir independently predictsoverall survival in patients who have metastatichormone-sensitive prostate cancer treatedwith androgen-deprivation therapy. Cancer.2009 Mar 1;115(5):981–7. doi: https://doi.org/10.1002/cncr.24064

  6. Thoma C. Validating early PSA response toenable improved treatment decisions. Nat RevUrol. 2016 May;13(5):239–239. doi: https://doi.org/10.1038/nrurol.2016.59

  7. Rescigno P, Lorente D, Bianchini D,Ferraldeschi R, Kolinsky MP, Sideris S, etal. Prostate-specific Antigen Decline After 4Weeks of Treatment with Abiraterone Acetateand Overall Survival in Patients with MetastaticCastration-resistant Prostate Cancer. Eur Urol.2016 Nov;70(5):724–31. doi: https://doi.org/10.1016/j.eururo.2016.02.055

  8. Hong SY, Cho DS, Kim SI, Ahn HS, Kim SJ.Prostate-specific antigen nadir and time toprostate-specific antigen nadir following maximalandrogen blockade independently predictprognosis in patients with metastatic prostatecancer. Korean J Urol. 2012 Sep;53(9):607–13.doi: https://doi.org/10.4111/kju.2012.53.9.607

  9. Sasaki T, Onishi T, Hoshina A. Nadir PSAlevel and time to PSA nadir following primaryandrogen deprivation therapy are the earlysurvival predictors for prostate cancer patientswith bone metastasis. Prostate Cancer ProstaticDis. 2011 Sep;14(3):248–52. doi: https://doi.org/10.1038/pcan.2011.14

  10. Tomioka A, Tanaka N, Yoshikawa M, MiyakeM, Anai S, Chihara Y, et al. Nadir PSA leveland time to nadir PSA are prognostic factorsin patients with metastatic prostate cancer.BMC Urol. 2014 Apr 29;14:33. doi: https://doi.org/10.1186/1471-2490-14-33




2020     |     www.medigraphic.com